Salix Pharmaceuticals Ltd. (SLXP) News

News for Salix Pharmaceuticals Ltd. (SLXP)

Sector News | Topic News

After Hours: $ 48.18

0.00 (0.00%)

Volume: 839

4:50 PM EST Feb 10, 2012

Tue, Feb 07, 2012

7:00 AM

Salix Pharmaceuticals Announces FDA Granting of Priority Review Designation for the Crofelemer NDA for Treatment of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy - Business Wire

Wed, Jan 04, 2012

10:00 AM

Salix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference - Business Wire

Tue, Dec 20, 2011

2:00 PM

Salix Pharmaceuticals Completes Acquisition of Oceana Therapeutics - Business Wire

7:00 AM

Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation - Business Wire

Wed, Dec 14, 2011

7:00 AM

Salix Pharmaceuticals Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea - Business Wire

Tue, Nov 29, 2011

7:00 AM

Salix Pharmaceuticals to Present at Oppenheimer Healthcare Conference - Business Wire

Wed, Nov 16, 2011

6:02 PM

FDA Advisory Committee Supports Proposed Clinical Trial Design to Evaluate Repeat Treatment Cycles of XIFAXAN® for Irritable Bowel Syndrome with Diarrhea - Business Wire

Mon, May 02, 2011

8:53 AM

Equity Research on Salix Pharmaceuticals Ltd. and Mylan Inc. -- Generic Drugs Gaining Ground - Marketwire

Financial Market Data powered by QuoteMedia.com. All rights reserved. View the Terms of Use
NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated.
RT Realtime, EOD End Of Day, PD Previous Day. PW Previous Week.

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.